儿科多发性硬化症的早期逆境和社会经济因素:一个病例对照研究

Sarah K G Jensen¹, Susana Camposano¹, Anne Berens¹+25

• ¹From the Pediatric Multiple Sclerosis and Related Disorders Program (S.K.G.J., S.C., L.A.B., M.P.G.), Department of Neurology, Boston Children's Hospital, Harvard Medical School; Boston College (S.K.G.J.), School of Social Work, MA; Stanford University School of Medicine (A.B.), Palo Alto, CA; Department of Pediatrics (M.W., T.C.C.), University of Utah, Salt Lake City; Pediatric Multiple Sclerosis Center (L.B.K., L.C., A.L.B.), NYU Grossman School of Medicine, New York; Pediatric Multiple Sclerosis Center at Loma Linda University Children's Hospital (G.S.A.), Loma Linda University, CA; Primary Children's Hospital (M.C.), University of Utah, Salt Lake City; Division of Child Neurology (T.C.), Department of Neurology, Massachusetts General Hospital, Boston; UCSD Pediatric MS Center (J.G.), San Diego, CA; Center for Pediatric-Onset Demyelinating Disease at the Children's of Alabama (Y.S.W.), University of Alabama, Birmingham; Children's National Medical Center (I.K.), Washington, DC; Baylor College of Medicine (T.E.L.), Houston, TX; Washington University Pediatric MS and other Demyelinating Disease Center (S.S.M.), Washington University in St. Louis, MO; Mellen Center for Multiple Sclerosis (M. Rensel), Cleveland Clinic, OH; Mayo Clinic (M. Rodriguez, J.-M.T.), Rochester, MN; Department of Neurology (J.W.R.), University of Utah, Salt Lake City; Ann and Robert H. Lurie Children's Hospital of Chicago (J.P.R.), IL; Division of Neurology (A.T.W.), Children's Hospital of Philadelphia, PA; The Pediatric MS Center at the Jacobs Neurological Institute (B.W.-G.), State University of New York at Buffalo; Division of Epidemiology and Genetic Epidemiology and Genomics Laboratory (L.F.B.), School of Public Health, University of California Berkeley; and UCSF Weill Institute for Neurosciences (E.W.), University of California San Francisco.